Patents by Inventor Frank D. Marcum
Frank D. Marcum has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11180067Abstract: A rapid loading sled for use during the transportation of wheeled vehicles via trailer or truck. The sled includes a body with a frame and deck that provide a low profile surface for loading and securing a wheeled vehicle to before the sled is loaded on a trailer or truck for transportation. The sled includes a sliding assembly to improve maneuverability during loading and a winch system for guiding the retractable cable of a winch during operation.Type: GrantFiled: March 27, 2018Date of Patent: November 23, 2021Inventor: Frank D. Marcum
-
Publication number: 20180272913Abstract: A rapid loading sled for use during the transportation of wheeled vehicles via trailer or truck. The sled includes a body with a frame and deck that provide a low profile surface for loading and securing a wheeled vehicle to before the sled is loaded on a trailer or truck for transportation. The sled includes a sliding assembly to improve maneuverability during loading and a winch system for guiding the retractable cable of a winch during operation.Type: ApplicationFiled: March 27, 2018Publication date: September 27, 2018Inventor: Frank D. Marcum
-
Patent number: 10076537Abstract: The invention provides compositions and methods of use thereof, in conjunction with the treatment and prevention of kidney and ureteral stones and related urinary tract conditions in man or in animals. Specifically provided are compositions formulated for direct instillation into the kidney, bladder, ureter, and urethra of the urinary tract before, during, and after the treatment of kidney and ureteral stones, such as with lithotripsy to alleviate or reduce at least one symptom associated therewith, and to facilitate the stones passing through the kidney, bladder, ureter, urethra and urinary tract. Compositions of the invention can comprise therapeutic amounts of: chondroitin sulfate and hyaluronan, and optionally include N-acetyl D-glucosamine.Type: GrantFiled: May 4, 2015Date of Patent: September 18, 2018Assignee: ARTHRODYNAMIC HOLDINGS, LLCInventor: Frank D. Marcum
-
Publication number: 20180221413Abstract: A pharmaceutical preparation and method for treating connective tissue damage in a mammal comprising administering to a mammal in need thereof a therapeutically effective amount of a glycosaminoglycan composition comprising chondroitin sulfate, hyaluronan, and N-acetyl D-glucosamine, wherein the connective tissue is skin.Type: ApplicationFiled: March 22, 2018Publication date: August 9, 2018Inventor: Frank D. Marcum
-
Patent number: 9937209Abstract: A pharmaceutical preparation for treating connective tissue damage in man and in animals, comprising a therapeutically effective amount of a glycosaminoglycan composition comprising chondroitin sulfate and hyaluronan, in combination with isolated stem cells. Methods of use and kits containing the glycosaminoglycan composition and materials for isolating stem cells and for treating connective tissue damage and repair of cartilage in man and in animals are also provided.Type: GrantFiled: November 16, 2015Date of Patent: April 10, 2018Assignee: ARTHRODYNAMIC HOLDINGS, LLCInventors: Frank D. Marcum, James Conway
-
Publication number: 20170166868Abstract: A culture media, media supplement, or soluble matrix for cryopreservation or enhanced regenerative cell growth in culture and maintenance of multi-lineage differentiation potentiation. The inventive culture media, media supplement, or soluble matrix comprises a GAG composition comprising a sulfated GAG, such as chondroitin sulfate. A soluble matrix, a cell administration package or kit comprising the soluble matrix and a device for cell administration, and a method of use thereof, for administration of regenerative cells for treating a joint disease or other weakened or damaged tissue comprising the specified GAG compositions are further provided.Type: ApplicationFiled: February 27, 2017Publication date: June 15, 2017Inventors: Michael Coleman, Ivone Bruno, Rudy Martinez, Amir Sanchez, Eckhard Alt, Frank D. Marcum, Paul Shealy
-
Patent number: 9593309Abstract: A culture media, media supplement, or soluble matrix for cryopreservation or enhanced regenerative cell growth in culture and maintenance of multi-lineage differentiation potentiation. The inventive culture media, media supplement, or soluble matrix comprises a GAG composition comprising a sulfated GAG, such as chondroitin sulfate. A soluble matrix, a cell administration package or kit comprising the soluble matrix and a device for cell administration, and a method of use thereof, for administration of regenerative cells for treating a joint disease or other weakened or damaged tissue comprising the specified GAG compositions are further provided.Type: GrantFiled: May 8, 2015Date of Patent: March 14, 2017Assignees: ArthroDynamic Holdings, LLC, InGeneron IncorporatedInventors: Michael Coleman, Ivone Bruno, Rudy Martinez, Amir Sanchez, Eckhard Alt, Frank D. Marcum, Paul Shealy
-
Publication number: 20170049803Abstract: The invention provides compositions and methods of use thereof, in conjunction with the treatment and prevention of kidney and ureteral stones and related urinary tract conditions in man or in animals. Specifically provided are compositions formulated for direct instillation into the kidney, bladder, ureter, and urethra of the urinary tract before, during, and after the treatment of kidney and ureteral stones, such as with lithotripsy to alleviate or reduce at least one symptom associated therewith, and to facilitate the stones passing through the kidney, bladder, ureter, urethra and urinary tract. Compositions of the invention can comprise therapeutic amounts of: chondroitin sulfate and hyaluronan, and optionally include N-acetyl D-glucosamine.Type: ApplicationFiled: May 4, 2015Publication date: February 23, 2017Inventor: Frank D. Marcum
-
Publication number: 20170043061Abstract: The invention provides lubricating compositions and methods of use thereof in man or in animals. Specifically, provided are lubricating compositions comprising effective amounts of chondroitin sulfate and hyaluronan, and optionally include N-acetyl D-glucosamine.Type: ApplicationFiled: May 4, 2015Publication date: February 16, 2017Inventor: Frank D. Marcum
-
Patent number: 9381211Abstract: The present invention provides a composition, and a method of use thereof, for treating connective tissue damage in man and in animals, which comprises a therapeutically effective amount of chondroitin sulfate, N-acetyl D-glucosamine, and hyaluronan (hyaluronic acid). Particularly, the present invention provides a composition, and a method of use thereof, for treating connective tissue damage including, but not limited to, arthritic disease, osteoarthritis, rheumatoid arthritis, osterochondrosis dessicans, cartilage damage, joint injury, joint inflammation, joint synovitis, degenerative joint disease (DJD), post surgical DJD, traumatic injury, fracture, tendon damage, ligament damage, skeletal damage, musculoskeletal damage, fiber damage, adipose tissue damage, small intestine tissue damage, blood cell damage, and plasma damage. Compositions for delivery of the present invention include those for parenteral, oral, and transmucosal delivery and for direct surgical placement onto the affected tissues.Type: GrantFiled: October 10, 2014Date of Patent: July 5, 2016Assignee: ARTHRODYNAMIC TECHNOLOGIES, ANIMAL HEALTH DIVISION, INC.Inventors: Frank D. Marcum, John William Seanor, Foster Harold Northrop
-
Publication number: 20160067282Abstract: A pharmaceutical preparation for treating connective tissue damage in man and in animals, comprising a therapeutically effective amount of a glycosaminoglycan composition comprising chondroitin sulfate and hyaluronan, in combination with isolated stem cells. Methods of use and kits containing the glycosaminoglycan composition and materials for isolating stem cells and for treating connective tissue damage and repair of cartilage in man and in animals are also provided.Type: ApplicationFiled: November 16, 2015Publication date: March 10, 2016Inventors: Frank D. Marcum, James Conway
-
Patent number: 9186375Abstract: A pharmaceutical preparation for treating connective tissue damage in man and in animals, comprising a therapeutically effective amount of a glycosaminoglycan composition comprising chondroitin sulfate, N-acetyl D-glucosamine, and hyaluronan, in combination with isolated stem cells. Methods of use and kits containing the glycosaminoglycan composition and materials for isolating stem cells and for treating connective tissue damage and repair of cartilage in man and in animals are also provided.Type: GrantFiled: July 10, 2012Date of Patent: November 17, 2015Assignee: ARTHRODYNAMIC TECHNOLOGIES, ANIMAL HEALTH DIVISION, INC.Inventors: Frank D. Marcum, James Conway
-
Publication number: 20150240211Abstract: A culture media, media supplement, or soluble matrix for cryopreservation or enhanced regenerative cell growth in culture and maintenance of multi-lineage differentiation potentiation. The inventive culture media, media supplement, or soluble matrix comprises a GAG composition comprising a sulfated GAG, such as chondroitin sulfate. A soluble matrix, a cell administration package or kit comprising the soluble matrix and a device for cell administration, and a method of use thereof, for administration of regenerative cells for treating a joint disease or other weakened or damaged tissue comprising the specified GAG compositions are further provided.Type: ApplicationFiled: May 8, 2015Publication date: August 27, 2015Inventors: Michael Coleman, Ivone Bruno, Rudy Martinez, Amir Sanchez, Eckhard Alt, Frank D. Marcum, Paul Shealy
-
Publication number: 20150030665Abstract: The present invention provides a composition, and a method of use thereof, for treating connective tissue damage in man and in animals, which comprises a therapeutically effective amount of chondroitin sulfate, N-acetyl D-glucosamine, and hyaluronan (hyaluronic acid). Particularly, the present invention provides a composition, and a method of use thereof, for treating connective tissue damage including, but not limited to, arthritic disease, osteoarthritis, rheumatoid arthritis, osterochondrosis dessicans, cartilage damage, joint injury, joint inflammation, joint synovitis, degenerative joint disease (DJD), post surgical DJD, traumatic injury, fracture, tendon damage, ligament damage, skeletal damage, musculoskeletal damage, fiber damage, adipose tissue damage, small intestine tissue damage, blood cell damage, and plasma damage. Compositions for delivery of the present invention include those for parenteral, oral, and transmucosal delivery and for direct surgical placement onto the affected tissues.Type: ApplicationFiled: October 10, 2014Publication date: January 29, 2015Inventors: Frank D. Marcum, John William Seanor, Foster Harold Northrop
-
Patent number: 8871742Abstract: The present invention provides a composition, and a method of use thereof, for treating connective tissue damage in man and in animals, which comprises a therapeutically effective amount of chondroitin sulfate, N-acetyl D-glucosamine, and hyaluronan (hyaluronic acid). Particularly, the present invention provides a composition, and a method of use thereof, for treating connective tissue damage including, but not limited to, arthritic disease, osteoarthritis, rheumatoid arthritis, osterochondrosis dessicans, cartilage damage, joint injury, joint inflammation, joint synovitis, degenerative joint disease (DJD), post surgical DJD, traumatic injury, fracture, tendon damage, ligament damage, skeletal damage, musculoskeletal damage, fiber damage, adipose tissue damage, blood cell damage, and plasma damage. Compositions for delivery of the present invention include those for parenteral, oral, and transmucosal delivery and for direct surgical placement onto the affected tissues.Type: GrantFiled: May 10, 2013Date of Patent: October 28, 2014Assignee: ArthroDynamic Technologies, Animal Health Division, Inc.Inventors: Frank D. Marcum, John William Seanor, Foster Harold Northrop
-
Publication number: 20140045784Abstract: The invention provides compositions and methods useful for the treatment and/or prevention of interstitial cystitis and/or a related urinary tract condition in man or in animals. Specifically, provided are compositions specially formulated for direct instillation into the bladder and/or parenteral use in the treatment and/or prevention of interstitial cystitis. Compositions adapted for direct instillation into the bladder and/or for systemic administration are provided comprised of therapeutic amounts of: chondroitin sulfate in combination with hyaluronan (hyaluronic acid) are provided. Compositions adapted for direct instillation into the bladder and/or for systemic administration are also provided comprised of therapeutic amounts of: chondroitin sulfate, hyaluronan (hyaluronic acid) and N-acetyl D-glucosamine.Type: ApplicationFiled: September 20, 2013Publication date: February 13, 2014Applicant: ArthroDynamic Technologies, Animal Health Division, Inc.Inventor: Frank D. Marcum
-
Patent number: 8580766Abstract: The invention provides compositions and methods useful for the treatment and/or prevention of interstitial cystitis and/or a related urinary tract condition in man or in animals. Specifically, provided are compositions specially formulated for direct instillation into the bladder and/or parenteral use in the treatment and/or prevention of interstitial cystitis. Compositions adapted for direct instillation into the bladder and/or for systemic administration are provided comprised of therapeutic amounts of: chondroitin sulfate in combination with hyaluronan (hyaluronic acid) are provided. Compositions adapted for direct instillation into the bladder and/or for systemic administration are also provided comprised of therapeutic amounts of: chondroitin sulfate, hyaluronan (hyaluronic acid) and N-acetyl D-glucosamine.Type: GrantFiled: January 30, 2009Date of Patent: November 12, 2013Assignee: ArthroDynamic Technologies, Animal Health Division, Inc.Inventor: Frank D. Marcum
-
Publication number: 20130251781Abstract: The present invention provides a composition, and a method of use thereof, for treating connective tissue damage in man and in animals, which comprises a therapeutically effective amount of chondroitin sulfate, N-acetyl D-glucosamine, and hyaluronan (hyaluronic acid). Particularly, the present invention provides a composition, and a method of use thereof, for treating connective tissue damage including, but not limited to, arthritic disease, osteoarthritis, rheumatoid arthritis, osterochondrosis dessicans, cartilage damage, joint injury, joint inflammation, joint synovitis, degenerative joint disease (DJD), post surgical DJD, traumatic injury, fracture, tendon damage, ligament damage, skeletal damage, musculoskeletal damage, fiber damage, adipose tissue damage, blood cell damage, and plasma damage. Compositions for delivery of the present invention include those for parenteral, oral, and transmucosal delivery and for direct surgical placement onto the affected tissues.Type: ApplicationFiled: May 10, 2013Publication date: September 26, 2013Applicant: ArthroDynamic Technologies, Animal Health Division , Inc.Inventors: Frank D. Marcum, John William Seanor, Foster Harold Northrop
-
Patent number: 8455458Abstract: The present invention provides a composition, and a method of use thereof for treating connective tissue damage in man and in animals, which comprises a therapeutically effective amount of chondroitin sulfate, N-acetyl D-glucosamine, and hyaluronan (hyaluronic acid). Particularly, the present invention provides a composition, and a method of use thereof, for treating connective tissue damage including, but not limited to, arthritic disease, osteoarthritis, rheumatoid arthritis, osterochondrosis dessicans, cartilage damage, joint injury, joint inflammation, joint synovitis, degenerative joint disease (DJD), post surgical DJD, traumatic injury, fracture, tendon damage, ligament damage, skeletal damage, musculoskeletal damage, fiber damage, adipose tissue damage, blood cell damage, and plasma damage. Compositions for delivery of the present invention include those for parenteral, oral, and transmucosal delivery and for direct surgical placement onto the affected tissues.Type: GrantFiled: June 21, 2007Date of Patent: June 4, 2013Assignee: Arthrodynamic Technologies, Animal Health Division, Inc.Inventors: Frank D. Marcum, John William Seanor, Foster Harold Northrop
-
Publication number: 20120276173Abstract: A pharmaceutical preparation for treating connective tissue damage in man and in animals, comprising a therapeutically effective amount of a glycosaminoglycan composition comprising chondroitin sulfate, N-acetyl D-glucosamine, and hyaluronan, in combination with isolated stem cells. Methods of use and kits containing the glycosaminoglycan composition and materials for isolating stem cells and for treating connective tissue damage and repair of cartilage in man and in animals are also provided.Type: ApplicationFiled: July 10, 2012Publication date: November 1, 2012Applicant: ArthroDynamic Technologies, Animal Health Division, Inc.Inventors: Frank D. Marcum, James Conway